Avant Sells $61 Million in Rights of Rotarix Sales
Avant Immunotherapeutics will raise up to $61 million
by selling a stake in the net royalties it expects from a vaccine that helps
prevent severe diarrhea in young children. The Needham company said it entered
into an agreement with Paul Royalty Fund II LP, to sell up to a $61 million
in interest in the net royalties Avant expects from global sales of its Rotarix
vaccine. Avant will get $50 million from the deal over the next year.
Boston Business Journal